H1B Report
Side-by-side comparison

AstraZeneca Pharmaceuticals LP vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
AstraZeneca Pharmaceuticals LP
DERank #FEIN 23-2967016
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricAstraZeneca Pharmaceuticals LPWIPRO LIMITED
Total filings75072,392
Certified %94.27%91.61%
Denied %1.60%0.37%
Withdrawn %1.60%1.37%
Cert-withdrawn %2.53%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateDENJ

Outcomes — AstraZeneca Pharmaceuticals LP

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 2.5%, Withdrawn 1.6%, Denied 1.6%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn2.5%
Withdrawn1.6%
Denied1.6%
Certified94.3%
Cert-withdrawn2.5%
Withdrawn1.6%
Denied1.6%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

AstraZeneca Pharmaceuticals LP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201010
FY201113
FY20126
FY20136
FY201412
FY201527
FY201622
FY201726
FY201865
FY201944
FY202054
FY202185
FY202229
FY202339
FY2024107
FY2025136
FY202669
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — AstraZeneca Pharmaceuticals LP

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.